Developing mRNA medicines to restore protein function.

We are a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

Learn More

Translate Bio

We are pioneering the translation of mRNA therapeutics into transformative medicines.

Recent News

07.31 2019
Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update
07.31 2019
Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis
07.15 2019
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
06.26 2019
Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency

View All

@TranslateBio